A Dana-Farber Cancer Institute study supports observation for men with low-risk prostate cancer
In a recent study of statistical models, Julia Hayes, MD, a medical oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and colleagues determined that men aged 65 or 75 diagnosed with low-risk, localized prostate cancers can forgo immediate treatment and safely opt for active surveillance, which will result not only in an improved quality of life but also reduced health care costs.
The study is published in the Annals of Internal Medicine.